The use of ramukirumab in the treatment of metastatic gastric cancer in real clinical practice
- Authors: Belyak N.P.1,2, Kutukova S.I1,3, Orlova R.V1,2, Zhukova N.V1,2, Erdniev S.P1, Zorina E.Y.1, Avramenko I.V1, Antimonik N.Y.1, Popova N.V1, Ivanova A.K1, Androsova A.V1
-
Affiliations:
- City Clinical Oncology Dispensary
- St. Petersburg State University
- Pavlov First St. Petersburg State Medical University
- Issue: Vol 26, No 7 (2019)
- Pages: 38-42
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312205
- DOI: https://doi.org/10.18565/pharmateca.2019.7.38-42
- ID: 312205
Cite item
Open Access
Access granted
Abstract
Full Text
About the authors
Nataliya P. Belyak
City Clinical Oncology Dispensary; St. Petersburg State University
Email: dmpb@mail.ru
PhD, Oncologist, Chemotherapy Department (№ 11), City Clinical Oncology Dispensary; Teaching Assistant at the Department of Oncology 56, Veteranov Avenue, St. Petersburg 198255, Russian Federation
S. I Kutukova
City Clinical Oncology Dispensary; Pavlov First St. Petersburg State Medical UniversitySt. Petersburg, Russia
R. V Orlova
City Clinical Oncology Dispensary; St. Petersburg State UniversitySt. Petersburg, Russia
N. V Zhukova
City Clinical Oncology Dispensary; St. Petersburg State UniversitySt. Petersburg, Russia
S. P Erdniev
City Clinical Oncology DispensarySt. Petersburg, Russia
E. Yu Zorina
City Clinical Oncology DispensarySt. Petersburg, Russia
I. V Avramenko
City Clinical Oncology DispensarySt. Petersburg, Russia
N. Yu Antimonik
City Clinical Oncology DispensarySt. Petersburg, Russia
N. V Popova
City Clinical Oncology DispensarySt. Petersburg, Russia
A. K Ivanova
City Clinical Oncology DispensarySt. Petersburg, Russia
A. V Androsova
City Clinical Oncology DispensarySt. Petersburg, Russia
References
- Van Cutsem E., Sagaert X., Topal B., et al. Gastric cancer. Lancet. 2016;388:2654-64. doi: 10.1016/S0140-6736(16)30354-3.
- Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064. doi: 10.1002/14651858.CD004064.pub3.
- Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97. doi: 10.1016/S0140-6736(10)61121-X.
- Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968-76. doi: 10.1200/JCO.2011.36.2236.
- Shah M.A., Bang Y.J., Lordick F., et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA. Oncol. 2016.
- Lordick F., Kang Y.K., Chung H.C., et al. Arbeitsgemeinschaft Internistische Onkologie, EXPAND investigators. capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open label phase 3 trial. Lancet. Oncol. 2013;14:490-99. Doi:10.1016/ S1470-2045(13)70102-5.
- Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673-84. Doi: 10.1136/ gutjnl-2011-301839. Epub 2012 Feb 7.
- Fuchs C.S., Tomasek J.,Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-9. doi: 10.1016/S0140-6736(13)61719-5.
- Wilke H., Muro K., Van Cutsem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet. Oncol. 2014;15:1224-35. doi: 10.1016/S1470-2045(14)70420-6.
Supplementary files
